^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lemtrada (alemtuzumab)

    i
    Other names: LDP 03, Campath-1H, LDP-03, LDP03
    Company:
    Bayer, Sanofi
    Drug class:
    CD52 inhibitor
    Related drugs:
    9d
    LemKids: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (clinicaltrials.gov)
    P3, N=16, Terminated, Genzyme, a Sanofi Company | Active, not recruiting --> Terminated; Enrolment formally closed earlier than planned due to recruitment challenges.
    Trial termination
    |
    Lemtrada (alemtuzumab)
    2ms
    Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Brigham and Women's Hospital | N=10 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Lemtrada (alemtuzumab)
    3ms
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial completion date: Sep 2030 --> Jul 2027
    Trial completion date
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
    4ms
    Cerebral tumefactive demyelinating lesions: clinical spectrum, long-term outcomes, and treatment. (PubMed, Acta Neurol Belg)
    Our findings demonstrate that TDLs represent a radiological phenotype associated within a spectrum of neuroinflammatory disorders, with MS being the most frequent underlying diagnosis in our cohort. Although their often alarming radiological appearance, the long-term clinical outcomes are generally favorable. Although most commonly associated with MS, diagnostic clarification through MOG IgG and anti-aquaporin-4 IgG antibody testing remains essential. Furthermore, the timely initiation of disease-modifying therapies following acute-phase treatments demonstrates clear benefits in long-term follow-up.
    Journal
    |
    IFNB1 (Interferon Beta 1)
    |
    fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
    5ms
    Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis. (PubMed, Neurol Res Pract)
    Among approved DMT for MS and RA, teriflunomide and anti-CD20 therapies are the most suitable options for moderately or highly active MS with comorbid RA. Cladribine may also be considered, while TNFα inhibitors are contraindicated.
    Review • Journal
    |
    IL6 (Interleukin 6)
    |
    Actemra IV (tocilizumab) • Lemtrada (alemtuzumab) • Cosentyx (secukinumab) • Kevzara (sarilumab) • Tysabri (natalizumab)
    5ms
    Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (clinicaltrials.gov)
    P3, N=100, Active, not recruiting, Haukeland University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2024 --> Nov 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab)
    8ms
    COMBAT-MS: COMparison Between All immunoTherapies for Multiple Sclerosis. (clinicaltrials.gov)
    P=N/A, N=3526, Completed, Karolinska Institutet | Active, not recruiting --> Completed
    Trial completion
    |
    Rituxan (rituximab) • fingolimod • Lemtrada (alemtuzumab) • Tysabri (natalizumab)
    10ms
    TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov)
    P=N/A, N=900, Active, not recruiting, Johns Hopkins University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Briumvi (ublituximab-xiiy) • Truxima (rituximab-abbs) • fingolimod • Lemtrada (alemtuzumab) • Tysabri (natalizumab)
    12ms
    Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? (PubMed, Sarcoidosis Vasc Diffuse Lung Dis)
    However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.
    Journal
    |
    CD52 (CD52 Molecule)
    |
    Campath (alemtuzumab) • Lemtrada (alemtuzumab)
    1year
    MS; FTY720: Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study (clinicaltrials.gov)
    P=N/A, N=4000, Completed, University of British Columbia
    New trial
    |
    fingolimod • Lemtrada (alemtuzumab) • Tysabri (natalizumab)
    over1year
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial primary completion date: Apr 2030 --> Jul 2027
    Trial primary completion date
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
    over1year
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)